Zydus Pharmaceuticals
Zydus Pharmaceuticals, a prominent player in the global pharmaceutical industry, is headquartered in the United States, with significant operations across North America, Europe, and Asia. Founded in 1995, the company has established itself as a leader in the development and manufacturing of generic and specialty pharmaceuticals, focusing on areas such as oncology, cardiovascular health, and diabetes management. Zydus Pharmaceuticals is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that includes injectables, biosimilars, and over-the-counter medications. The company has achieved notable milestones, including numerous FDA approvals and a strong presence in the biosimilars market, positioning it as a trusted name in healthcare. With a dedication to improving patient outcomes, Zydus continues to expand its reach and impact within the pharmaceutical landscape.
DitchCarbon Score
How does Zydus Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zydus Pharmaceuticals's score of 21 is lower than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zydus Pharmaceuticals's reported carbon emissions
In 2023, Zydus Pharmaceuticals reported a total Scope 1 and Scope 2 emission intensity of approximately 0.0000153 kg CO2e per million of turnover, adjusted for Purchasing Power Parity (PPP). For 2024, the company reported an increased emission intensity of about 0.0000386 kg CO2e per million of turnover, indicating a rise in emissions relative to revenue. Currently, Zydus Pharmaceuticals has not disclosed specific absolute emissions figures or set formal reduction targets. The absence of detailed emissions data across Scope 1, Scope 2, and Scope 3 suggests that the company may still be in the early stages of formalising its climate commitments. As the pharmaceutical industry increasingly prioritises sustainability, Zydus Pharmaceuticals is expected to enhance its climate strategies and transparency in emissions reporting to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zydus Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
